Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.90% | -1.38% | 105.14% | -37.43% | 354.48% |
| Total Depreciation and Amortization | 24.62% | -1.78% | 3.39% | -4.62% | 3.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -120.61% | 299.59% | -143.66% | 1,016.68% | -108.63% |
| Change in Net Operating Assets | -404.10% | 153.39% | 32.74% | -51.27% | -22,592.86% |
| Cash from Operations | -63.51% | 186.24% | 85.33% | -32.67% | -33.35% |
| Capital Expenditure | -21.99% | -23.02% | -12.43% | -0.89% | -10.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 79.69% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 58.35% | -150.73% | 92.52% | -334.11% | 84.01% |
| Cash from Investing | 6.05% | -62.55% | 45.26% | -74.51% | 52.03% |
| Total Debt Issued | -100.00% | -- | -100.00% | 6,461,100.00% | -100.00% |
| Total Debt Repaid | 99.99% | -596.14% | 144.61% | -160.77% | 198.48% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -112.92% | -2.30% | 42.32% | 41.57% | -360.41% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.02% | 0.13% | -0.05% | -15.28% | 0.22% |
| Other Financing Activities | 16.89% | 0.66% | 95.57% | -1,395.21% | 2.96% |
| Cash from Financing | -642.15% | 142.65% | -190.23% | 711.84% | -206.72% |
| Foreign Exchange rate Adjustments | -311.67% | -88.49% | 108.87% | 130.76% | -288.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.33% | 2,170.35% | 261.39% | -72.68% | -169.74% |